Editas Medicine pricing shares at $16 for year's first IPO: reports
Editas Medicine Inc. EDIT, +0.00% priced shares for its initial public offering at the low end of the range, according to media reports late Tuesday, for what will be 2016’s first IPO. Editas will price 5.9 million shares at $16 a share, at the low end of its $16 to $18 range, to raise $94.4 million. That give Editas a market valuation of $571 million, according to Reuters. Cambridge, Mass.-based Editas develops treatments for genetic-based diseases via editing gene sequences.
Most Recent Posts:
At Globe Summit, Mass General Brigham panelists explore the impact of AI
Exploring AI’s Impact on Industry, left to right: panelists, Marc Succi, MD, Daniela Rus and Paul English,…
Perspectives on WMIF 2023 from Garibyan
Lilit Garibyan, MD, PhD, a dermatologist at the Wellman Center for Photomedicine and an associate professor of…
The Inflation Reduction Act: Responses From Experts on Implications for Biopharmaceutical Innovation
September 21, 2023—Two panel discussions on the Inflation Reduction Act at the World Medical Innovation Forum in…
